InspireMD (NSPR)
(Delayed Data from NSDQ)
$2.69 USD
-0.10 (-3.58%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $2.75 +0.06 (2.23%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NSPR 2.69 -0.10(-3.58%)
Will NSPR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NSPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NSPR
CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains?
InspireMD Launches CGuard Prime Carotid Stent System in the U.S.
NSPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates
Globus Medical (GMED) Lags Q1 Earnings and Revenue Estimates
IQVIA Holdings (IQV) Surpasses Q1 Earnings and Revenue Estimates
Other News for NSPR
InspireMD Inc (NSPR) Director Gary Roubin Purchases 41,322 Shares
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Thursday's Intraday Session
InspireMD (NSPR) Secures $58 Million to Advance Carotid Stent System
InspireMD (NSPR) Welcomes Raymond W. Cohen to Board of Directors